Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...
Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Tandem Diabetes Care (TNDM) begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with ...
ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...
The Abbott FreeStyle Libre 2 can be used as a real-time continuous glucose monitor (CGM) with an upgrade to the FreeStyle LibreLink app. Please note, the below information comes with a critical update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results